262.80
Bio Rad Laboratories Inc stock is traded at $262.80, with a volume of 161.77K.
It is up +0.37% in the last 24 hours and up +2.43% over the past month.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
See More
Previous Close:
$261.82
Open:
$265.2
24h Volume:
161.77K
Relative Volume:
0.67
Market Cap:
$7.09B
Revenue:
$2.58B
Net Income/Loss:
$759.90M
P/E Ratio:
9.4137
EPS:
27.9168
Net Cash Flow:
$374.60M
1W Performance:
-2.61%
1M Performance:
+2.43%
6M Performance:
-6.26%
1Y Performance:
+7.26%
Bio Rad Laboratories Inc Stock (BIO) Company Profile
Name
Bio Rad Laboratories Inc
Sector
Industry
Phone
(510) 724-7000
Address
1000 ALFRED NOBEL DRIVE, HERCULES
Compare BIO vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
BIO
Bio Rad Laboratories Inc
|
262.80 | 7.09B | 2.58B | 759.90M | 374.60M | 27.92 |
|
ABT
Abbott Laboratories
|
108.03 | 187.72B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
336.77 | 128.88B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
87.14 | 111.88B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
69.13 | 102.58B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
81.81 | 47.52B | 6.07B | 1.06B | 1.34B | 1.8063 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-24 | Upgrade | Citigroup | Neutral → Buy |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Apr-03-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-07-23 | Initiated | UBS | Buy |
| Jun-16-23 | Initiated | Wells Fargo | Overweight |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jan-28-22 | Reiterated | Citigroup | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-17-18 | Initiated | Goldman | Buy |
| Sep-20-18 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-16-18 | Downgrade | CL King | Buy → Neutral |
| Jul-13-17 | Initiated | Wells Fargo | Outperform |
| Jun-28-17 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-18-17 | Initiated | Deutsche Bank | Hold |
| Oct-13-16 | Initiated | CL King | Buy |
| May-06-15 | Reiterated | Jefferies | Buy |
| Dec-18-09 | Initiated | Maxim Group | Buy |
| Nov-06-09 | Initiated | Jefferies & Co | Buy |
| Jul-17-09 | Initiated | Soleil | Buy |
| Sep-26-07 | Initiated | Banc of America Sec | Buy |
| Feb-23-07 | Downgrade | Robert W. Baird | Outperform → Neutral |
View All
Bio Rad Laboratories Inc Stock (BIO) Latest News
Mangrove Partners IM LLC Invests $35.57 Million in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Perbak Capital Partners LLP Purchases 5,423 Shares of Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Portolan Capital Management LLC Has $13.02 Million Stock Position in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
10,425 Shares in Bio-Rad Laboratories, Inc. $BIO Purchased by Magnetar Financial LLC - MarketBeat
Bio-Rad Laboratories, Inc. $BIO Shares Purchased by Natixis Advisors LLC - MarketBeat
Capital Research Global Investors Makes New Investment in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Molecular Diagnostics Market Outlook: Set to Grow at 10%+ CAGR Through 2031 as Precision Medicine and Genetic Testing Advance, Says Mordor Intelligence - GlobeNewswire Inc.
Assessing Whether Bio-Rad Laboratories (BIO) Looks Undervalued After Recent Share Price Softness - Yahoo Finance
Bio-Rad Laboratories Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Chipmakers Recap: Is Bio Rad Laboratories Inc stock forming a triangle patternJuly 2025 Intraday Action & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Dimensional Fund Advisors LP Purchases 63,370 Shares of Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Bio-Rad Laboratories Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
Published on: 2026-03-07 12:19:08 - baoquankhu1.vn
Bio-Rad outlines flat to 1% currency-neutral revenue growth for 2025 while expanding ddPCR partnerships - MSN
BIO Should I Buy - Intellectia AI
TD Asset Management Inc Purchases 7,386 Shares of Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Bio-Rad Laboratories, Inc. $BIO Shares Bought by GW&K Investment Management LLC - MarketBeat
Portfolio Shifts: Will Bio Rad Laboratories Inc outperform its industry peersQuarterly Risk Review & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Teachers Retirement System of The State of Kentucky Has $10.22 Million Stake in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Analysts Issue Forecasts for BIO FY2028 Earnings - MarketBeat
Fisher Asset Management LLC Lowers Stock Position in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Medical Dry Fluorescence Immunoassay Analyzer Market Is Going - openPR.com
Automatic Blood Group Diagnostic Instrument Market Is Going - openPR.com
Assessing Bio-Rad (BIO) Valuation After Mixed Share Price Performance And Recurring Revenue Shift - simplywall.st
Roubaix Capital LLC Buys Shares of 8,112 Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Zacks Research Has Bearish Estimate for BIO Q1 Earnings - MarketBeat
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating a 16.36% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Digital PCR Market to Reach US$ 14.37 Billion by 2033 at 9.8% CAGR; - openPR.com
Artisan Partners Limited Partnership Has $24.22 Million Position in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Westfield Capital Management Co. LP Increases Stock Holdings in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Is It Time To Reconsider Bio-Rad Laboratories (BIO) After Its Prolonged Share Price Slump - simplywall.st
Bio-Rad Laboratories, Inc. $BIO Shares Sold by Vanguard Group Inc. - MarketBeat
A Look At Bio Rad Laboratories (BIO) Valuation After Recent Share Price Weakness - simplywall.st
(BIO) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Molecular Biology Analyzers Market Set to Boom by 2033: - openPR.com
Microfluidics Research Report 2026-2035: A $20.73 Billion - GlobeNewswire
Microfluidics Research Report 2026-2035: A $20.73 Billion Market by 2030 with Thermo Fisher Scientific, PerkinElmer, Dolomite, Agilent Technologies, Bio-Rad Laboratories, and Fluidigm Leading - Yahoo Finance
Bio-Rad Laboratories (NYSE:BIO.B) Shares Pass Below 200-Day Moving AverageTime to Sell? - MarketBeat
Weekly Earnings: What is the long term forecast for Bio Rad Laboratories Inc stockJuly 2025 Reactions & High Win Rate Trade Alerts - baoquankhu1.vn
International Markets and Bio-Rad (BIO): A Deep Dive for Investors - Yahoo Finance
Bio-Rad Laboratories, Inc. $BIO Shares Sold by ICICI Prudential Asset Management Co Ltd - MarketBeat
Blood Grouping Reagents Market Top Key Players -Grifols, Roche, - openPR.com
Hemocytometer Market Is Going to Boom Rapidly With Top Key - openPR.com
CenterBook Partners LP Has $2.56 Million Holdings in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
4 Undervalued Life Sciences Tools & Services Stocks for Thursday, February 19 - AAII
Bio-Rad Updates Investors on Sartorius Strategic Investment Metrics - TipRanks
Sartorius 2025 results summarized in Bio-Rad (NYSE: BIO) update - Stock Titan
Bio-Rad Laboratories, Inc. (BIO) achieves modest revenue growth and robust free cash flow growth - MSN
Bio-Rad Laboratories, Inc. (BIO) Achieves Modest Revenue Growth and Robust Free Cash Flow Growth - Finviz
Risk Hedge: Is RBOT still a buy after recent gains2025 Institutional Moves & Stock Timing and Entry Methods - baoquankhu1.vn
Bio-Rad's Q4 Earnings Miss Estimates, Revenues Surpass, Stock Down - Yahoo Finance
Bio Rad Laboratories Inc Stock (BIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):